Related / Contacts
Related / News
Press Releases • Feb 26, 2016 07:10 GMT
Sobi today announced its results for the fourth quarter and full year 2015. Revenues for the full year totalled SEK 3,228 M (2,607), an increase of 24 per cent compared to previous year. Revenues for the fourth quarter were 15 per cent higher year-on-year and the product revenues grew 21 per cent, with Orfadin® (nitisinone) and Kineret® (anakinra) delivering strong performance.
Bo Jesper Hansen to step down as Chairman of Sobi™ – Håkan Björklund to be nominated as new Chairman of the Board
Press Releases • Feb 26, 2016 07:15 GMT
Sobi Chairman of the Board, Bo Jesper Hansen, MD, PhD, has informed the Sobi’s nomination committee that he will not stand for re-election at the 2016 annual general meeting of shareholders (AGM). The Nomination Committee will propose that the shareholders elect Håkan Björklund, PhD, as the new Chairman of the Board for Sobi.